Please wait...


Generic Name: galsulfase (gal SUL fase)
Brand Names: Naglazyme
Naglazyme is used to treat patients with mucopolysaccharidosis type VI. Learn about side effects, interactions and indications.
  • Prescription Settings

Prices and coupons of Naglazyme

Current Location: 20149 (Ashburn)
Change Location?

Enter your zip code

Please wait while the prices are loaded...

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
Naglazyme (galsulfase) contains an enzyme that occurs naturally in the body in healthy people. Some people lack this enzyme because of a genetic disorder. Galsulfase helps replace this missing enzyme in such people. Naglazyme is used to treat some of the symptoms of a genetic condition called mucopolysaccharidosis VI (MYOO-koe-pol-ee-SAK-a-rye-DOE-sis type 6), or MPS VI, also called Maroteaux-Lamy syndrome. MPS VI is a metabolic disorder in which the body lacks the enzyme needed to break down certain sugars and proteins. These substances can build up in the body, causing enlarged organs, abnormal bone structure, changes in facial features, breathing problems, heart problems, vision or hearing loss, and changes in mental or physical abilities. Learn more

Naglazyme Side Effects

Naglazyme Side Effects

Note: This document contains side effect information about galsulfase. Some of the dosage forms listed on this page may not apply to the brand name Naglazyme.

In Summary

Common side effects of Naglazyme include: severe infusion related reaction, conjunctivitis, rigors, chest pain, development of igg antibodies, dyspnea, infusion related reaction, otalgia, pain, and pharyngitis. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to galsulfase: intravenous solution

Along with its needed effects, galsulfase (the active ingredient contained in Naglazyme) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking galsulfase:

Less common

  • Blurred or decreased vision
  • chest pain
  • difficult or labored breathing
  • dizziness
  • headache
  • hernia of the naval
  • nervousness
  • pounding in the ears
  • slow or fast heartbeat
  • swelling of the face
  • tightness in the chest

Incidence not known

  • Back pain
  • bluish lips or skin
  • confusion
  • cough
  • dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
  • fever, chills, or sweating
  • hives or welts
  • joint pain
  • large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
  • loss of bladder control
  • loss of bowel control
  • nausea or vomiting
  • paralysis of the limbs
  • stomach pain

Some side effects of galsulfase may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Diarrhea
  • ear pain
  • loss of appetite

Less common

  • Body aches or pain
  • burning, dry, or itching eyes
  • congestion
  • dryness or soreness of the throat
  • excessive tearing
  • loss of or increase in reflexes
  • runny or stuffy nose
  • tender, swollen glands in the neck
  • trouble with swallowing
  • unusual tiredness or weakness
  • voice changes

Incidence not known

  • Difficulty with moving
  • loss of voice
  • muscle pain or stiffness
  • sneezing

For Healthcare Professionals

Applies to galsulfase: intravenous solution


The most frequently reported adverse reactions included rash, pain, urticaria, pyrexia, pruritus, chills, headache, nausea, vomiting, abdominal pain, and dyspnea.

The most frequently reported adverse reactions requiring interventions are infusion-related reactions.


Frequency not reported: Anaphylaxis/anaphylactoid reaction, allergic reaction


Very common (10% or more): Rash (21%), angioedema, urticaria, pruritus

Common (1% to 10%): Erythema


Very common (10% or more): Abdominal pain (47%), gastroenteritis (11%), umbilical hernia (11%), nausea, vomiting


Very common (10% or more): Infusion reactions (56%), ear pain (42%), pain (32%), chills/rigors (21%), chest pain (16%), malaise (11%), hearing impairment (11%), pyrexia

Infusion reactions, which occurred in 56% of patients across 5 clinical studies were defined as adverse reactions occurring during infusions or until the end of the infusion day. Infusion reactions were observed as early as week 1 and as late as week 146 of treatment and occurred during multiple infusions, however, not always in consecutive weeks. The most common signs/symptoms included pruritus, vomiting, abdominal pain, nausea, hypertension, headache, chest pain, erythema, cough, hypotension, angioedema, respiratory distress, tremor, conjunctivitis, malaise, bronchospasm, and arthralgia.


Very common (10% or more): Hypertension (11%)

Common (1% to 10%): Hypotension

Frequency not reported: Pallor, bradycardia, tachycardia, cyanosis, shock

Nervous system

Very common (10% or more): Areflexia (11%), headache

Common (1% to 10%): Tremor

Frequency not reported: Paresthesia


Very common (10% or more): Dyspnea (21%), pharyngitis (11%), nasal congestion (11%)

Common (1% to 10%): Apnea, cough, respiratory distress, asthma, bronchospasm

Frequency not reported: Laryngeal edema, hypoxia, tachypnea, sleep apnea

Postmarketing reports: Respiratory failure


Very common (10% or more): Arthralgia (42%)


Very common (10% or more): Conjunctivitis (21%), corneal opacity (11%)


Very common (10% or more): Development of antidrug antibodies (98%)

During clinical trials, 53 out of 54 patients tested positive for antidrug IgG antibodies within 4 to 8 weeks of treatment. In the placebo controlled study, 19 patients were evaluated for a potential relationship between development of antidrug antibodies to clinical outcome measures. While all 19 patients developed antidrug antibodies, there was no consistent predictive relationship between total antibody titer, neutralizing or IgE antibodies, and infusion-associated reactions, urinary glycosaminoglycan (GAG) levels, or endurance measures.


Postmarketing reports: Membranous nephropathy


Postmarketing reports: Thrombocytopenia

Editorial References and Review

Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.

Source: Drugs.com Naglazyme